1
|
Ammirati E, Marchetti D, Colombo G, Pellicori P, Gentile P, D'Angelo L, Masciocco G, Verde A, Macera F, Brunelli D, Occhi L, Musca F, Perna E, Bernasconi DP, Moreo A, Camici PG, Metra M, Oliva F, Garascia A. Estimation of Right Atrial Pressure by Ultrasound-Assessed Jugular Vein Distensibility in Patients With Heart Failure. Circ Heart Fail 2024; 17:e010973. [PMID: 38299348 DOI: 10.1161/circheartfailure.123.010973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 12/19/2023] [Indexed: 02/02/2024]
Abstract
BACKGROUND Clinical evaluation of central venous pressure is difficult, depends on experience, and is often inaccurate in patients with chronic advanced heart failure. We assessed the ultrasound-assessed internal jugular vein (JV) distensibility by ultrasound as a noninvasive tool to identify patients with normal right atrial pressure (RAP ≤7 mm Hg) in this population. METHODS We measured JV distensibility as the Valsalva-to-rest ratio of the vein diameter in a calibration cohort (N=100) and a validation cohort (N=101) of consecutive patients with chronic heart failure with reduced ejection fraction who underwent pulmonary artery catheterization for advanced heart failure therapies workup. RESULTS A JV distensibility threshold of 1.6 was identified as the most accurate to discriminate between patients with RAP ≤7 versus >7 mm Hg (area under the receiver operating characteristic curve, 0.74 [95% CI, 0.64-0.84]) and confirmed in the validation cohort (receiver operating characteristic, 0.82 [95% CI, 0.73-0.92]). A JV distensibility ratio >1.6 had predictive positive values of 0.86 and 0.94, respectively, to identify patients with RAP ≤7 mm Hg in the calibration and validation cohorts. Compared with patients from the calibration cohort with a high JV distensibility ratio (>1.6; n=42; median RAP, 4 mm Hg; pulmonary capillary wedge pressure, 11 mm Hg), those with a low JV distensibility ratio (≤1.6; n=58; median RAP, 8 mm Hg; pulmonary capillary wedge pressure, 22 mm Hg; P<0.0001 for both) were more likely to die or undergo a left ventricular assist device implant or heart transplantation (event rate at 2 years: 42.7% versus 18.2%; log-rank P=0.034). CONCLUSIONS Ultrasound-assessed JV distensibility identifies patients with chronic advanced heart failure with normal RAP and better outcomes. REGISTRATION URL: https://www.clinicaltrials.gov; Unique identifier: NCT03874312.
Collapse
Affiliation(s)
- Enrico Ammirati
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Davide Marchetti
- Cardiology Department, Galeazzi-Sant'Ambrogio Hospital, Milan, Italy (D.M.)
| | - Giada Colombo
- Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, Italy (G.C., M.M.)
| | - Pierpaolo Pellicori
- School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom (P.P.)
| | - Piero Gentile
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Luciana D'Angelo
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Gabriella Masciocco
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Alessandro Verde
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Francesca Macera
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Dario Brunelli
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Lucia Occhi
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Francesco Musca
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Enrico Perna
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Davide P Bernasconi
- Bicocca Bioinformatics Biostatistics and Bioimaging Center, School of Medicine and Surgery, University of Milano-Bicocca, Italy (D.P.B.)
| | - Antonella Moreo
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Paolo G Camici
- Cardiovascular Research Center, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Hospital, Milan, Italy (P.G.C.)
| | - Marco Metra
- Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, Italy (G.C., M.M.)
| | - Fabrizio Oliva
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| | - Andrea Garascia
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy (E.A., P.G., L.D., G.M., A.V., F. Macera, D.B., L.O., F. Musca, E.P., A.M., F.O., A.G.)
| |
Collapse
|
5
|
Hudson SR, Chan D, Ng LL. Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study. J R Soc Med 2017; 109:337-46. [PMID: 27609799 DOI: 10.1177/0141076816661316] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVES This study aimed to develop an inexpensive, readily available prognostic indicator in acute decompensated heart failure patients to guide management and improve outcome. Prognostic biomarkers for heart failure exist but are expensive and not routinely performed. Increasing plasma volume has been associated with worse outcomes. SETTING UK University Teaching Hospital. DESIGN Observational Cohort study. PARTICIPANTS 967 patients with acute decompensated heart failure. METHODS Haemoglobin and haematocrit were measured at admission and discharge and were used to calculate the plasma volume change using the Strauss-Davis-Rosenbaum formula. MAIN OUTCOME MEASURES Endpoints were death and the composite of death and/or heart failure hospitalisation. Change in plasma volume was added to ADHERE scoring to determine predictive value. RESULTS During follow-up, 536 died and 626 died or were hospitalised with heart failure. Multivariable Cox models showed change in plasma volume was an independent predictor of mortality (hazard ratio (HR) [95% confidence interval (CI)]: 1.150 [1.031-1.283], p = 0.012) and death or heart failure hospitalisation (HR: 1.138 [1.029-1.259], p = 0.012). Kaplan-Meier analysis of change in plasma volume tertiles for outcome measures showed significant difference for the top tertile compared to the lower two. Multivariable analysis of change in plasma volume with ADHERE scoring showed change in plasma volume change remained an independent predictor of death (HR: 1.138 [1.026-1.261], p = 0.015) and death or heart failure hospitalisation (HR: 1.129 [1.025-1.243], p = 0.014). CONCLUSIONS Change in plasma volume over an admission can be used for prognostication and adds value to the ADHERE score. Change in plasma volume can be easily and inexpensively calculated from routine blood tests. Clinically, this may facilitate targeted treatment of acute decompensated heart failure patients at greatest risk.
Collapse
Affiliation(s)
- Sarah R Hudson
- Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, UK NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester LE3 9QP, UK
| | - Daniel Chan
- Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, UK NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester LE3 9QP, UK
| | - Leong L Ng
- Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, UK NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester LE3 9QP, UK
| |
Collapse
|
6
|
Chernomordik F, Berkovitch A, Schwammenthal E, Goldenberg I, Rott D, Arbel Y, Elis A, Klempfner R. Short- and Long-Term Prognostic Implications of Jugular Venous Distension in Patients Hospitalized With Acute Heart Failure. Am J Cardiol 2016; 118:226-31. [PMID: 27287063 DOI: 10.1016/j.amjcard.2016.04.035] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2015] [Revised: 04/11/2016] [Accepted: 04/11/2016] [Indexed: 01/06/2023]
Abstract
The present study was designed to assess the role of jugular venous distension (JVD) as a predictor of short- and long-term mortality in a "real-life" setting. The independent association between the presence of admission JVD and the 30-day, 1- and 10-year mortality was assessed among 2,212 patients hospitalized with acute heart failure (HF) who were enrolled in the Heart Failure Survey in Israel (2003). Independent predictors of JVD finding in study patients included: the presence of significant hyponatremia (odds ratio [OR] 1.48; p = 0.03), reduced left ventricular ejection fraction ([LVEF] OR 1.24; p = 0.03), anemia (OR 1.3; p = 0.01), New York Heart Association III to IV (OR 1.34; p <0.01) and age >75 years (OR 1.32; p = 0.01). The presence of JVD versus its absence at the time of HF hospitalization was associated with increased 30-day mortality (7.2% vs 4.9%, respectively; p = 0.02), 1-year (33% vs 28%, respectively; p <0.001), and greater 10-year mortality (91.8% vs 87.2%, respectively; p <0.001). Consistently, interaction term analysis demonstrated that the presence of JVD at the time of the index HF hospitalization was independently associated with a significant increased risk for 10-year mortality, with a more pronounced effect among younger patients, patients with reduced LVEF, preserved renal function, and chronic HF. In conclusion, in patients admitted with HF, JVD is associated with specific risk factors and is independently associated with increased risk of both short- and long-term mortality. These findings can be used for improved risk assessment and management of this high-risk population.
Collapse
|
10
|
Collins SP, Schauer DP, Gupta A, Brunner H, Storrow AB, Eckman MH. Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure. Am J Emerg Med 2009; 27:293-302. [PMID: 19328373 DOI: 10.1016/j.ajem.2008.02.025] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2008] [Revised: 02/21/2008] [Accepted: 02/22/2008] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND The ED disposition of patients with non-high-risk acute decompensated heart failure (ADHF) is challenging. To help address this problem, we investigated the cost-effectiveness of different ED disposition strategies. METHODS We constructed a decision analytic model evaluating the cost-effectiveness of 3 possible ED ADHF disposition strategies in a 60-year-old man: (1) discharge home from the ED; (2) observation unit (OU) admission; (3) inpatient admission. Base case patients had no high-risk features. We used Medicare costs and the national physician fee schedule to capture ED, OU, and hospital costs, including costs of complications and death. All analyses were conducted using Decision Maker software (University of Medicine and Dentistry of New Jersey, Newark, NJ). RESULTS Compared to ED discharge, OU admission had a reasonable marginal cost-effectiveness ratio ($44 249/quality adjusted life year), whereas hospital admission had an unacceptably high marginal cost-effectiveness ratio ($684 101/quality adjusted life year). Sensitivity analyses demonstrated that as the risk of early (within 5 days) and late (within 30 days) readmission exceeded 36% and 74%, respectively, in those discharged from the ED, OU admission became less costly and more effective than ED discharge. Similarly, an increase in relative risk of both early and late death in those discharged from the ED improves the marginal cost-effectiveness ratio of OU admission. Finally, as postdischarge event rates increase in those discharged from the OU, hospital admission became more cost-effective. CONCLUSION Observation unit admission for patients with non-high-risk ADHF has a societally acceptable marginal cost-effectiveness ratio compared to ED discharge. However, as ED and OU discharge event rates increase, hospital admission becomes the more cost-effective strategy.
Collapse
Affiliation(s)
- Sean P Collins
- Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
| | | | | | | | | | | |
Collapse
|